Pediatric carriage rates have remained stable since 2018, and invasive pneumococcal disease incidence in young children was less than half that at the start of the vaccination program, with more than ...

The Australian government announced last week there's a new vaccine for pneumococcal disease on the National Immunization Program for all children. Pneumococcus is also responsible for most ...

The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older. The vaccine, which will be sold under the name Capvaxive, is designed to protect against ...

Credit: Merck. Capvaxive consists of pneumococcal polysaccharides from 21 serotypes, including 8 unique serotypes: 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B. Capvaxive consists of pneumococcal ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Please provide your email address to receive an email when new articles are posted on . Over the past several years, adult pneumococcal vaccine recommendations have evolved based on the development of ...

In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...

Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine candidate. The study showed strong immune responses in infants compared ...

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...